Home

Intelligence

Services

Subscriptions

News

About Us

Sign In

 

Document Preview

Asset and Liability Transfer Agreement

 

Click "Add to Cart" button to purchase document. 
Documents are emailed immediately after purchase. 
You can also browse documents by
title, category, or company... or click here for help finding documents.

 

Title:

Asset and Liability Transfer Agreement

Entities:

Comdisco Holding Co. Inc.; International Business Machines Corp.; Metabasis Therapeutics, Inc.; Pfizer, Inc.; University of California, San Diego; University of Michigan, Ann Arbor; University of Virginia; Pillsbury Winthrop LLP; Gensia Sicor Inc.; Sankyo Co, Ltd.

Date:

2004

Size:

Preview shows 11KB of 145KB total

Price:

$51

ID:

#271976

 

 

► Miscellany ► Transfer ► Misc. Transfer Agreements
► Miscellany ► Fortune 100
► Services ► Rental & Leasing
► Technology ► Computer Hardware
► Services ► Legal
► Miscellany ► Universities
► Biotech & Drugs ► Pharmaceutical Preparations

 

 

Start of Preview


ASSET AND LIABILITY TRANSFER AGREEMENT

between

METABASIS THERAPEUTICS, INC.,

and

GENSIA SICOR INC.

December 17, 1997


ASSET AND LIABILITY TRANSFER AGREEMENT

        THIS ASSET AND LIABILITY TRANSFER AGREEMENT (this "Agreement") is made and entered into as of the 17th day of December, 1997, between METABASIS THERAPEUTICS, INC., a Delaware corporation ("Metabasis"), and GENSIA SICOR INC., a Delaware corporation ("Gensia Sicor").

RECITALS:

        WHEREAS, subject to the terms and conditions of this Agreement, Gensia Sicor wishes to sell and transfer certain assets and certain liabilities of its research and development business to Metabasis.

        WHEREAS, subject to the terms and conditions of this Agreement, Metabasis desires to purchase such assets in consideration for the assumption of such liabilities, the issuance to Gensia Sicor of certain shares of Subordinated Convertible Preferred Stock of Metabasis (the "Subordinated Preferred Stock"), and the payment to Gensia Sicor of a certain amount in cash, all as more fully described below.

        WHEREAS, simultaneous with the Closing (as defined below), Sankyo Co, Ltd., a Japanese corporation ("Sankyo"), and Metabasis have entered into a Stock Purchase Agreement dated as of the date hereof (the "Sankyo Stock Purchase Agreement"), pursuant to which Sankyo is purchasing from Metabasis, and Metabasis is issuing to Sankyo, certain shares of Series A Preferred Stock of Metabasis (the "Series A Preferred Stock") on the terms and conditions thereof, and thereafter Metabasis will no longer be a wholly-owned subsidiary of Gensia Sicor.

        WHEREAS, the parties hereto desire to enter into this Agreement for the purpose of setting forth certain representations, warranties and covenants made to each other as an inducement to the execution and delivery of this Agreement and the conditions precedent to the consummation of the asset and liability transfer and the transactions related thereto.

        NOW, THEREFORE, in consideration of the mutual covenants and conditions contained herein, the parties hereto agree as follows:

ARTICLE 1

PURCHASE AND SALE OF ASSETS

        1.1    Purchase and Sale.    Subject to the terms and conditions and upon satisfaction of the conditions contained in this Agreement (which term shall include all exhibits and schedules attached hereto) and in reliance upon the representations, warranties an covenants contained herein, on the Closing Date (as hereinafter defined), Gensia Sicor shall sell, assign, transfer and deliver to Metabasis, and Metabasis shall purchase and acquire from Gensia Sicor, all of Gensia Sicor's right, title and interest in, to and under all the franchises, rights, business, properties and other assets, tangible or intangible, real, personal or mixed, listed below in this Section 1.1 (collectively, the "Assets"), used in or accrued or accruing to the business of discovering and developing proprietary pharmaceutical products (including drugs intended to address diabetes, pain, inflammation, cardiovascular, epilepsy and other conditions) as currently conducted at the Gensia Sicor facility located at 9390 Towne Centre Drive, San Diego., California (the "Transferred Business"), free and clear of Liens (as hereinafter defined), except Permitted Liens (as hereinafter defined):